(CNN)Experts are worried some Americans are letting up too early — at a critical time when looming dangers are threatening to wipe out the progress the US has made in its battle against Covid-19.
At least a dozen state leaders have eased Covid-19 restrictions this month, often citing improving Covid-19 trends and growing vaccination numbers. At the same time, air travel is hitting pandemic-era records and the first spring break crowds have begun descending on Florida and other sunny regions while cases of a dangerous variant are on the rise.
The Transportation Security Administration said it screened more than 1.2 million people at airports across the US on Monday — bringing the total number of US air travelers since Thursday to about 6.4 million. That’s the highest number of any five-day period of the pandemic.
In Florida, spring breakers have begun packing shores with some Miami Beach officials reporting swelling crowds and precautions going out the window.
It’s a combination of all those factors, officials fear, that could lay the groundwork for another spike.
“We have seen footage of people enjoying spring break festivities, maskless,” Centers for Disease Control and Prevention Director Dr. Rochelle Walensky said Monday. “This is all in the context of still 50,000 cases per day.”
So is another surge inevitable?
“We could go in either direction,” emergency physician Dr. Leana Wen told CNN on Monday. “What happens now is really up to us and whether we keep up masking and avoiding indoor gatherings as we should be until the point that we’re vaccinated.”
You asked, we answered: Your top questions about Covid-19 and vaccines
A dangerous variant will be dominant soon
Experts have said safety measures will be crucial because multiple variants of the virus are circulating — including the highly contagious B.1.1.7 variant that was first identified in the UK.
B.1.1.7 is projected to become the dominant variant in the US by the end of this month or early April, Walensky said Monday. Because it is highly contagious, it could cause a surge in cases, and vaccination levels are not high enough to stop such a spike, experts have said.
“The way the variants spread is by letting our guard down,” Dr. Richard Besser, the former acting CDC director, told CNN on Monday. “By not wearing masks, by not social distancing. If we can hang in there for a few more months, there will be enough vaccine for every adult in America to be vaccinated.”
“Then we can truly let go of some of the restrictions that are in place. But if we do this too quickly, we could see an increase in cases, we could see a backslide that is occurring in many European countries and that does not have to be the outcome here in America,” he added.
Research published last week suggested that the variant was associated with an estimated 64% higher risk of dying from Covid-19.
Another peer-reviewed study has linked the variant to a higher risk of death, according to a paper accepted by the journal Nature. This time, the risk of death from the variant was estimated around 55% higher than earlier strains after adjusting for a number of factors like age, sex, and where and when tests were conducted.
A subsequent analysis in the study that accounted for missing and potentially miscategorized test results found the overall increased risk of death may be somewhat higher — around 61% more than earlier strains.
The study was not able to factor in vaccination nor could it show why the variant might be more deadly than earlier strains.
Researchers have said current vaccines generally offer good protection against the B.1.1.7 variant.
Daily vaccination numbers hit record levels
But there is good news: Vaccinations are ramping up and experts are hopeful Americans will be able to see a semblance of normality by the summertime.
Data updated by the CDC on Monday shows the country hit a seven-day average of about 2.4 million Covid-19 vaccine doses administered per day, a new record.
That comes as more states expanded their eligibility requirements for vaccinations.
In Mississippi, Gov. Tate Reeves announced Monday the state would be opening up appointments to all residents who are 16 and older starting Tuesday.
In West Virginia, Gov. Jim Justice expanded the list of pre-existing medical conditions that make residents eligible to receive a vaccine.
“We’re on a glide slope to being able to get our lives back to normal, and that’s what we want more than anything,” Justice said.
So far, more than 71 million Americans have received at least one dose of a Covid-19 vaccine, according to CDC data. More than 38 million have been fully vaccinated — roughly 11.5% of the US population.
Moderna’s Phase 2/3 vaccine trial for kids up to 11 starts
The first children have been vaccinated in Moderna’s Phase 2/3 Covid-19 vaccine trial for ages 6 months to 11 years, the company said Tuesday.
The clinical trial, called the KidCOVE study, will enroll approximately 6,750 children of those ages in the US and Canada.
The trial is broken into two parts. In part one, different dosages of the vaccine are being tested on the children. Children between the ages of 6 months and 1 year will receive two doses of the vaccine spaced about 28 days apart, at doses of either 25, 50 or 100 micrograms. Children ages 2-11 will receive two doses of the vaccine spaced about 28 days apart, at either 50 or 100 micrograms.
Those findings will determine which dose will be used in the second part, when the trial will also include children who are given a saline placebo, which does nothing. The children will be followed for 12 months after their second injection.
Moderna is doing the tests to see if the vaccine protects children from getting sick if they come into contact with coronavirus, according to the clinical trial’s patient information website.
Moderna also has been running a separate Phase 2/3 trial — for adolescents ages 12 to 17.
Moderna’s vaccine is currently authorized only for people ages 18 and up. So far, the youngest age OK’d for any of the three Covid-19 inoculations authorized in the US is 16, for the Pfizer vaccine.
Pfizer has been running a trial of its vaccine for ages 12 to 15.
Johnson & Johnson has announced plans to study its vaccine in children ages 12 to 17, and its CEO has said he thinks the company could have a vaccine approved for ages below 18 by September.
Source: Read Full Article